Inhibition of progression of androgen-dependent prostate LNCaP tumors to androgen independence in SCID mice by oral caffeine and voluntary exercise

Nutrition and Cancer

Volumn 64, Issue 7, 2012, Pages 1029-1037

  Zheng, Xi ^a,b   Cui, Xiao Xing ^a   Huang, Mou Tuan ^a   Liu, Yue ^a   Wagner, George C ^c   Lin, Yong ^d,e   Shih, Weichung Joe ^d,e   Lee, Mao Jung ^a   Yang, Chung S ^a,d   Conney, Allan H ^a,b,d  

^a RUTGERS UNIVERSITY   (United States)

^b GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CAFFEINE; CASPASE 3; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL STRAIN LNCAP; CONTROLLED STUDY; MALE; MITOSIS; MOUSE; NONHUMAN; PROSTATE TUMOR; SCID MOUSE; TREADMILL; TREADMILL EXERCISE; TUMOR GROWTH;

ADMINISTRATION, ORAL; ANDROGENS; ANIMALS; APOPTOSIS; CAFFEINE; CASPASE 3; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXERCISE TEST; INTERLEUKIN-6; MALE; MICE; MICE, SCID; MOTOR ACTIVITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84867761946     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.716899     Document Type: Article

References (47)

1. Jemal, A, Siegel, R, Xu, J, and, Ward, E. 2010. Cancer statistics, 2010. CA Cancer J Clin, 60: 277-300.
2. Devlin, H, and, Mudryj, M. 2009. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett, 274: 177-186.
3. Schrder, F. 2008. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol, 53: 1129-1137.
4. Chi, K, Bjartell, A, Dearnaley, D, Saad, F, Schrder, F. 2009. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol, 56: 594-605.
5. Morris, M, and, Scher, H. 2002. Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surg Oncol, 11: 13-23.
6. Pilat, M, Kamradt, J, and, Pienta, K. 1998. Hormone resistance in prostate cancer. Cancer Metastasis Rev, 17: 373-381.
7. So, A, Gleave, M, Hurtado-Col, A, and, Nelson, C. 2005. Mechanisms of the development of androgen independence in prostate cancer. World J Urol, 23: 1-9.
8. Raghavan, D, Koczwara, B, and, Javle, M. 1997. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer, 33: 566-574.
9. Huang, M-T, Xie, J-G, Wang, Z-Y, Ho, C-T, Lou, Y-R. 1997. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res, 57: 2623-2629.
10. Michna, L, Wagner, G C, Lou, Y-R, Xie, J-G, Peng, Q-Y. 2006. Inhibitory effects of voluntary running wheel exercise on UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis, 27: 2108-2115.
11. Lu, Y-P, Lou, Y-R, Lin, Y, Shih, W, Huang, M-T. 2001. Inhibitory effects of orally administered green tea, black tea, and caffeine on skin carcinogenesis in mice previously treated with ultraviolet B light (high-risk mice): relationship to decreased tissue fat. Cancer Res, 61: 5002-5009.
12. Lu, Y-P, Lou, Y-R, Li, X-H, Xie, J-G, Brash, D. 2000. Stimulatory effect of oral administration of green tea or caffeine on ultraviolet light-induced increases in epidermal wild-type p53, p21(WAF1/CIP1), and apoptotic sunburn cells in SKH-1 mice. Cancer Res, 60: 4785-4791.
13. Lu, Y P, Lou, Y R, Nolan, B, Peng, Q Y, Xie, J G. 2006. Stimulatory effect of voluntary exercise or fat removal (partial lipectomy) on apoptosis in the skin of UVB light-irradiated mice. Proc Natl Acad Sci USA, 103: 16301-16306.
14. Lu, Y-P, Lou, Y-R, Xie, J-G, Peng, Q-Y, Liao, J. 2002. Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci USA, 99: 12455-12460.
15. Lu, Y-P, Lou, Y-R, Peng, Q, Nghiem, P, and, Conney, A H. 2011. Caffeine decreases phospho-Chk1 (Ser317) and increases mitotic cells with cyclin B1 and caspase 3 in tumors from UVB-treated mice. Cancer Prev Res, 4: 1118-1125.
16. Zheng, X, Cui, X-X, Gao, Z, Zhao, Y, Lin, Y. 2010. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res, 3: 114-124.
17. Zheng, X, Cui, X-X, Huang, M-T, Liu, Y, Shih, W. 2008. Inhibitory effect of voluntary running wheel exercise in the growth of human pancreas Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice. Oncol Rep, 19: 1583-1588.
18. Zheng, X, Cui, X X, Avila, G E, Huang, M T, Liu, Y. 2007. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res, 13: 5480-5487.
19. Kot, M, and, Daniel, W. 2007. Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep, 59: 296-305.
20. Lindsey, J K. 1993. Models for Repeated Measurements, 89-96. Oxford, UK: Claredon Press.
21. de Leon, J, Diaz, F J, Rogers, T, Browne, D, Dinsmore, L. 2003. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry, 27: 165-171.
22. Norager, C B, Jensen, M B, Weimann, A, and, Madsen, M R. 2006. Metabolic effects of caffeine ingestion and physical work in 75-year old citizens. A randomized, double-blind, placebo-controlled, cross-over study. Clin Endocrinol (Oxf), 65: 223-228.
23. Lu, Y-P, Lou, Y-R, Peng, Q-Y, Xie, J-G, Nghiem, P. 2008. Effect of caffeine on the ATR/Chk1 pathway in the epidermis of UVB-irradiated mice. Cancer Res, 68: 2523-2529.
24. Kawamoto, H, Koizumi, H, and, Uchikoshi, T. 1997. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in non-malignant and malignant breast lesions. Am J Pathol, 150: 15-23.
25. Mashal, R D, Lester, S, Corless, C, Richie, J P, Chandra, R. 1996. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res, 56: 4159-4163.
26. Kushner, J, Bradley, G, Young, B, and, Jordan, R C. 1999. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J Oral Pathol Med, 28: 77-81.
27. Murakami, H, Furihata, M, Ohtsuki, Y, and, Ogoshi, S. 1999. Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Arch, 434: 153-158.
28. Maddison, L A, Huss, W J, Barrios, R M, and, Greenberg, N M. 2004. Differential expression of cell cycle regulatory molecules and evidence for a cyclin switch during progression of prostate cancer. Prostate, 58: 335-344.
29. Gregory, C W, Johnson, R TJ, Presnell, S C, Mohler, J L, and, French, F S. 2001. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J Androl, 22: 537-548.
30. Gomez, L A, de Las Pozas, A, Reiner, T, Burnstein, K, and, Perez-Stable, C. 2007. Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Molecular Cancer Theraputics, 6: 1534-1543.
31. Laskin, D L, and, Laskin, J D. 2010. Inflammation and cancer. In Cancer Medicine, Edited by: Hong, W K, Bast, R C Jr., Hait, W, Kufe, D W and Pollock, R E. 270-278. Shelton, CT: People's Medical Publishing House.
32. Mantovani, A, Garlanda, C, and, Allavena, P. 2010. Molecular pathway and targets in cancer-related inflammation. Ann Med, 42: 161-170.
33. Smith, P C, Hobisch, A, Lin, D L, Culig, Z, and, Keller, E T. 2001. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev, 12: 33-40.
34. Chun, J Y, Nadiminty, N, Dutt, S, Lou, W, Yang, J C. 2009. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res, 15: 4815-4822.
35. Hobisch, A, Eder, I E, Putz, T, Horninger, W, Bartsch, G. 1998. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res, 58: 4640-4645.
36. Chung, T D, Yu, J J, Spiotto, M T, Bartkowski, M, and, Simons, J W. 1999. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate, 38: 199-207.
37. Smith, P C, and, Keller, E T. 2001. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate, 48: 47-53.
38. Wallner, L, Dai, J, Escara-Wilke, J, Zhang, J, Yao, Z. 2006. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res, 66: 3081-3095.
39. Carillo, J, and, Benitez, J. 2000. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet, 39: 127-153.
40. Antonelli, J, Jones, L, Banez, L, Thomas, J-A, Anderson, K. 2009. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol, 182: 2226-2231.
41. Richman, E L, Kenfield, S A, Stampfer, M J, Paciorek, A, Carroll, P R. 2011. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res, 71: 3889-3895.
42. Park, C-H, Myung, S-K, Kim, T-Y, Seo, H G, Jeon, Y-J. 2010. KORMA Study Group. Coffee consumption and risk of prostate cancer: a meta-analysis of epidemiological studies. BJU Int, 106: 762-769.
43. Wilson, K M, Kasperzyk, J L, Rider, J R, Kenfield, S, van Dam, R M. 2011. Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. J Natl Cancer Inst, 103: 1-9.
44. McCusker, R R, Feuhrlein, B, Goldberger, B A, Gold, M S, and, Cone, E J. 2006. Caffeine content of decaffeinated coffee. J Anal Toxicol, 30: 611-613.
45. Tsai, H, DAmico, A, Sadetsky, N, Chen, M, and, Carroll, P. 2007. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst, 44: 1516-1524.
46. Saigal, C, Gore, J L, Krupski, T L, Hanley, J, Schonlau, M. 2007. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer, 110: 1493-1500.
47. DAmico, A, Denham, J, Crook, J, Chen, M, Goldhaber, S. 2007. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infractions. J Clin Oncol, 25: 2420-2425.